Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published May 2015
  • Article
  • Info & Metrics
  • PDF
Loading

βIII-Tubulin Mediates Brain Metastasis

Kanojia et al. Page 1152

Breast cancer cells that metastasize to the brain overexpress genes predominantly expressed within neuronal tissues. In this study, Kanojia and colleagues demonstrate that a neuronal predominant marker, βIII-tubulin, is overexpressed in both brain metastatic breast cancer cell models and human brain metastatic tissue. Knockdown of βIII-tubulin decreased invasion, brain micrometastatic lesions, and improved survival in a mouse model of breast cancer brain metastases. These results establish βIII-tubulin as a molecular marker of brain metastatic breast cancer as well as a bona fide target for therapeutic intervention of breast cancer brain metastases.

Efficient Intracellular Delivery of Tissue Factor Antibody–Drug Conjugates

de Goeij et al. Page 1130

A better understanding of the target requirements is needed for optimal intracellular delivery of cytotoxic agents by antibody–drug conjugates (ADCs). de Goeij and colleagues compared the efficacy of ADCs targeting tissue factor (TF), HER2 and EGFR, with the target characteristics required for an ADC approach. Unlike HER2 and EGFR, TF was constitutively being internalized and degraded in tumor cells. When conjugated with the tubulin inhibitor duostatin-3, TF-ADC was relatively potent in reducing tumor growth compared with EGFR- and HER2-ADCs. It was found that the high turnover of TF on tumor cells might be the reason why this protein is specifically suitable for an ADC approach.

TSC2 Loss in Liver Cancer Predicts Everolimus Response

Huynh and Hao et al. Page 1224

Everolimus (mTORC1 inhibitor) failed to show survival benefits in unselected hepatocellular carcinoma (HCC) patients (EVOLVE-1 clinical trial) and thus biomarkers predicting everolimus response in HCC are urgently needed. From a proteomic biomarker study, Huynh, Hao, and colleagues discovered the loss of TSC2 in HCC cell lines and xenograft models and demonstrated its predictive value for everolimus sensitivity. In addition, the authors found that a subset of EVOLVE-1 patients with TSC2-null/low tumors benefited from everolimus treatment. TSC2 loss was also enriched in Asian HBV+ HCC. These data indicate that TSC2 loss is a promising patient selection biomarker for the treatment of HCC patients with everolimus.

An Enhanced Newcastle Disease Virus for Melanoma Treatment

Cuadrado-Castano et al. Page 1247

Newcastle disease virus (NDV) is a promising viral candidate for cancer therapy. Exploring new ways to improve its therapeutic potential, Cuadrado-Castano and colleagues developed the recombinant rNDV-B1/Fas virus, armed with the human tumor necrosis receptor Fas. Overexpression of Fas receptor upon rNDV-B1/Fas virus infection resulted in coactivation of both extrinsic and intrinsic apoptotic pathways leading to earlier and higher tumor cell cytotoxicity as compared to wild-type NDV virus infection. In vivo, rNDV-B1/Fas virotherapy promoted complete tumor remission in melanoma-bearing mice. Expression of proapoptotic factors during cancer virotherapy might be a general strategy to improve antitumor clinical responses.

  • ©2015 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 14 (5)
May 2015
Volume 14, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Ther May 1 2015 (14) (5) 1085;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Ther May 1 2015 (14) (5) 1085;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • βIII-Tubulin Mediates Brain Metastasis
    • Efficient Intracellular Delivery of Tissue Factor Antibody–Drug Conjugates
    • TSC2 Loss in Liver Cancer Predicts Everolimus Response
    • An Enhanced Newcastle Disease Virus for Melanoma Treatment
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement